BioSpace7h
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
BioSpace7h
Takeda Puts Over $1.1B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis ...
Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
Study finds annual healthcare costs per patient are significantly higher than previously described– HHT costs are higher than other ...
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments ...
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, ...
FierceBiotech10h
Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl
The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...